P3 Health Partners (NASDAQ:PIII) Posts Earnings Results, Beats Expectations By $1.26 EPS

Key Points

• P3 Health Partners beat quarterly earnings expectations, reporting a loss of $0.63 per share versus the consensus estimate of a $1.89 loss. Revenue reached $386.38 million, above analyst expectations of $377.80 million.
• Shares rose $1.25 to $12.83 in midday trading, while the stock remained volatile, with a 12-month range of $1.52 to $16.89 and a market capitalization of approximately $92.95 million.
• Analysts maintain a consensus “Hold” rating and an average price target of $14.00; ratings include one Buy, two Holds and one Sell.

P3 Health Partners (NASDAQ:PIII - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.26, FiscalAI reports. The business had revenue of $386.38 million for the quarter, compared to analyst estimates of $377.80 million.

P3 Health Partners Stock Performance

Shares of PIII stock traded up $1.25 during mid-day trading on Monday, hitting $12.83. 277,176 shares of the stock traded hands, compared to its average volume of 569,285. P3 Health Partners has a twelve month low of $1.52 and a twelve month high of $16.89. The company's 50-day simple moving average is $10.98 and its 200-day simple moving average is $6.33. The firm has a market cap of $92.95 million, a price-to-earnings ratio of -0.33 and a beta of 1.63.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on PIII shares. UBS Group set a $14.00 target price on P3 Health Partners in a research note on Friday, May 15th. Wall Street Zen raised P3 Health Partners to a "hold" rating in a report on Saturday, July 4th. Weiss Ratings upgraded shares of P3 Health Partners from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, May 28th. Lake Street Capital reiterated a "buy" rating and issued a $14.00 target price (up from $4.00) on shares of P3 Health Partners in a research report on Friday, May 15th. Finally, TD Cowen reissued a "hold" rating and set a $14.00 target price (up from $3.00) on shares of P3 Health Partners in a research note on Friday, May 22nd. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, P3 Health Partners has a consensus rating of "Hold" and an average target price of $14.00.

P3 Health Partners Company Profile

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company's platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company's core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source